Painful diabetic neuropathy (PDN) in the United States is defined as having had numbness, loss of feeling, or painful sensations in the feet within the last three months. PDN is managed by multiple…
MARKET OUTLOOK Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins, but DRG anticipates that the number of treatment options will grow over the next ten years. Intensive…
Market Outlook Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only other oral targeted therapy, besides Celgene’s PDE-4 inhibitor, Otezla,…
MARKET OUTLOOK Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins, but DRG anticipates that the number of treatment options will grow over the next ten years. Intensive…
Market Outlook Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only other oral targeted therapy, besides Celgene’s PDE-4 inhibitor, Otezla,…
The wet age-related macular degeneration (AMD) therapy market in the United States is unique given the dominance of Genentech’s Avastin, an oncology drug that is used off-label to treat wet AMD,…
Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data…
Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data…
Myelodysplastic syndromes ( MDS ) is a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and risk of progression to acute myeloid leukemia ( AML ). Management…
IBS-C is an indication ripe for emerging therapies; only three drugs have a label approval for this disease across the major U.S. and European markets, although many therapies are used off-label…
IBS-C is an indication ripe for emerging therapies; only three drugs have a label approval for this disease across the major U.S. and European markets, although many therapies are used off-label…
An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form of MS…
MARKET OUTLOOK Treatment of rheumatoid arthritis (RA) is typically initiated with cost-effective conventional DMARDs, such as methotrexate. For RA patients who are refractory to conventional…
ACS is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. Current drug targets for ACS, particularly those in the acute…
ACS is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. Current drug targets for ACS, particularly those in the acute…